Microcap Ledger NEUROONE MEDICAL TECHNOLOGIES Corp $NMTC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Eden Prairie, MN
- Fiscal year end
- September 30
- Shares outstanding
- 9,105,763 [10-Q 2026-08-13]
What the company doesAI summary of filing
NeuroOne Medical Technologies develops medical devices for diagnosis and treatment of neurological disorders, including brain conditions like epilepsy and Parkinson's disease, pain management, and drug delivery. The company has received FDA 510(k) clearance for four devices: Evo Cortical electrodes, Evo sEEG electrodes, OneRF Brain Ablation System, and OneRF TN Ablation System for trigeminal neuralgia treatment. It generates revenue through a distribution agreement with Zimmer Biomet, which earned approximately $9.1 million in fiscal 2025, while additional products including spinal cord stimulation systems and basivertebral nerve ablation devices remain in development stages. [10-K 2025-12-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | $6.73M | −$5.83M | −$5.53M | $2.05M | [10-Q 2026-08-13] |
| FY ended Sep 2025 | $9.10M | −$3.61M | −$2.84M | $6.57M | [10-K 2025-12-17] |
| FY ended Sep 2024 | $3.45M | −$12.32M | −$11.01M | $1.46M | [10-K 2025-12-17] |
- Quarterly cash burn
- −$1.84M
- Cash runway Estimate
- ~3.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-05-09 | 49,817,835 | [10-Q 2025-05-13] |
| 2025-08-12 | 49,999,519 | [10-Q 2025-08-14] |
| 2025-12-12 | 50,413,148 | [10-K 2025-12-17] |
| 2026-01-20 | 50,431,588 | [10-K/A 2026-01-23] |
| 2026-02-13 | 50,525,995 | [10-Q 2026-02-17] |
| 2026-05-08 | 8,619,876 | [10-Q 2026-05-12] |
| 2026-06-10 | 8,702,982 | [10-Q/A 2026-06-12] |
| 2026-08-11 | 9,105,763 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2024-08-30; declared effective 2024-09-13 [S-3 2024-08-30]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-11-05. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-11-05 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-05] |
| 2025-05-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-09] |
| 2025-01-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-10] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-27 | Wambeke David J. | buy | 33,333 | $2.01 | [4 2026-09-08] |
| 2026-06-30 | Christianson Mark | sell | 10,000 | $3.18 | [4 2026-07-02] |
| 2026-04-03 | Mills Jason Richard | grant | 41,929 | — | [4 2026-04-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 8-K | Results of operations; Other events |
| 2026-08-27 | 8-K | Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-12 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-12 | 8-K | Other events |
| 2026-06-12 | 10-Q/A | Amended report |
| 2026-05-22 | 8-K | Non-reliance on prior financials; Regulation FD disclosure |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-04 | 8-K | Other events |
Alerts for $NMTC
Email me when NEUROONE MEDICAL TECHNOLOGIES Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.